Background: Mild cognitive impairment (MCI), termed Zu’f al-Dimagh in Unani medicine, is a clinically significant precursor to dementia with limited pharmacological options. Objective: To evaluate the efficacy and safety of Khamira Gawzaban Sada (KGS), a standardized Pharmacopoeial Unani compound, in patients with MCI. Methods: An open-label, single-arm pilot trial enrolled 100 participants (screened n=150) with MMSE scores of 10–23. KGS was administered orally at 10 g/day for six weeks. Primary outcome was change in MMSE score; secondary outcome was patient-reported Quality of Life (QoL). Safety was monitored through adverse event surveillance, laboratory parameters, and vital signs at baseline, Week 2, Week 4, and Week 6. Results: Mean MMSE scores improved significantly from 16.2 (±2.8) at baseline to 22.4 (±1.9) at Week 6 (p<0.001). QoL domain scores demonstrated consistent improvement across all measured domains. No serious adverse events were recorded. Conclusion: KGS demonstrates preliminary efficacy and acceptable tolerability in MCI. Randomized controlled trials with larger cohorts are warranted to confirm these findings.